Menu Search
Equities

Henry Schein Inc

HSIC:NSQ

Henry Schein Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)76.89
  • Today's Change1.81 / 2.41%
  • Shares traded2.61m
  • 1 Year change+10.36%
  • Beta0.8636
Data delayed at least 15 minutes, as of Nov 25 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy3
Outperform2
Hold6
Sell3
Strong Sell0

Share price forecast in USD

The 10 analysts offering 12 month price targets for Henry Schein, Inc. have a median target of 74.50, with a high estimate of 83.00 and a low estimate of 55.00. The median estimate represents a -0.77% decrease from the last price of 75.08.
High10.5%83.00
Med-0.8%74.50
Low-26.7%55.00

Earnings history & estimates in USD

On Nov 05, 2024, Henry Schein, Inc. reported 3rd quarter 2024 earnings of 1.22 per share. This result was in line with the consensus of the 12 analysts following the company and under-performed last year's 3rd quarter results by 7.58%.
The next earnings announcement is expected on Feb 25, 2025.
Average growth rate+6.92%
Henry Schein, Inc. reported annual 2023 earnings of 4.50 per share on Feb 27, 2024.
Average growth rate+9.87%
More ▼

Revenue history & estimates in USD

Henry Schein, Inc. had 3rd quarter 2024 revenues of 3.17bn. This missed the 3.24bn consensus estimate of the 11 analysts following the company. This was 3.73% above the prior year's 3rd quarter results.
Average growth rate+0.16%
Henry Schein, Inc. had revenues for the full year 2023 of 12.34bn. This was 2.44% below the prior year's results.
Average growth rate+5.86%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.